scholarly journals 1827P European Society for Medical Oncology (ESMO)/International Society of Geriatric Oncology (SIOG) Joint Working Group (WG) survey on management of older patients with cancer

2021 ◽  
Vol 32 ◽  
pp. S1237-S1238
Author(s):  
C. Baldini ◽  
E.G.C. Brain ◽  
S. Rostoft ◽  
L. Biganzoli ◽  
V. Goede ◽  
...  
2014 ◽  
Vol 32 (24) ◽  
pp. 2595-2603 ◽  
Author(s):  
Hans Wildiers ◽  
Pieter Heeren ◽  
Martine Puts ◽  
Eva Topinkova ◽  
Maryska L.G. Janssen-Heijnen ◽  
...  

Purpose To update the International Society of Geriatric Oncology (SIOG) 2005 recommendations on geriatric assessment (GA) in older patients with cancer. Methods SIOG composed a panel with expertise in geriatric oncology to develop consensus statements after literature review of key evidence on the following topics: rationale for performing GA; findings from a GA performed in geriatric oncology patients; ability of GA to predict oncology treatment–related complications; association between GA findings and overall survival (OS); impact of GA findings on oncology treatment decisions; composition of a GA, including domains and tools; and methods for implementing GA in clinical care. Results GA can be valuable in oncology practice for following reasons: detection of impairment not identified in routine history or physical examination, ability to predict severe treatment-related toxicity, ability to predict OS in a variety of tumors and treatment settings, and ability to influence treatment choice and intensity. The panel recommended that the following domains be evaluated in a GA: functional status, comorbidity, cognition, mental health status, fatigue, social status and support, nutrition, and presence of geriatric syndromes. Although several combinations of tools and various models are available for implementation of GA in oncology practice, the expert panel could not endorse one over another. Conclusion There is mounting data regarding the utility of GA in oncology practice; however, additional research is needed to continue to strengthen the evidence base.


2020 ◽  
Vol 11 (7) ◽  
pp. 1175-1181 ◽  
Author(s):  
Isacco Desideri ◽  
Sophie Pilleron ◽  
Nicolò Matteo Luca Battisti ◽  
Fabio Gomes ◽  
Nienke de Glas ◽  
...  

2014 ◽  
Vol 15 (9) ◽  
pp. e404-e414 ◽  
Author(s):  
Jean-Pierre Droz ◽  
Matti Aapro ◽  
Lodovico Balducci ◽  
Helen Boyle ◽  
Thomas Van den Broeck ◽  
...  

2007 ◽  
Vol 25 (14) ◽  
pp. 1832-1843 ◽  
Author(s):  
Stuart M. Lichtman ◽  
Hans Wildiers ◽  
Etienne Chatelut ◽  
Christopher Steer ◽  
Daniel Budman ◽  
...  

The elderly comprise the majority of patients with cancer and are the recipients of the greatest amount of chemotherapy. Unfortunately, there is a lack of data to make evidence-based decisions with regard to chemotherapy. This is due to the minimal participation of older patients in clinical trials and that trials have not systematically evaluated chemotherapy. This article reviews the available information with regard to chemotherapy and aging provided by a task force of the International Society of Geriatric Oncology (SIOG). Due to the lack of prospective data, the conclusions and recommendations made are a consensus of the participants. Extrapolation of data from younger to older patients is necessary, particularly to those patients older than 80 years, for which data is almost entirely lacking. The classes of drugs reviewed include alkylators, antimetabolites, anthracyclines, taxanes, camptothecins, and epipodophyllotoxins. Clinical trials need to incorporate an analysis of chemotherapy in terms of the pharmacokinetic and pharmacodynamic effects of aging. In addition, data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient.


2020 ◽  
Vol 11 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Schroder Sattar ◽  
Cindy Kenis ◽  
Kristen Haase ◽  
Peggy Burhenn ◽  
Petra Stolz-Baskett ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document